Excitingly, dupilumab as a human IgG4к monoclonal antibody blocking IL-4 receptor (a shared receptor for IL-4 and IL-13) is the first biologic approved both for AD (FDA in 2017 and EMA in 2019) and asthmatic patients (USA and Europe in 2018) (196). The gene discussed is IL4; the disease is Alzheimer disease.